Compositions and methods for stabilizing flaviviruses with improved formulations
AssigneeTakeda Vaccines, Inc.
InventorsJill Ann Livengood, Linda Marie Strange, Steven Michael Erb
Life of this patent
Estimating the term…
Abstract
Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.
Claims29
A lyophilized dengue virus composition comprising:
- live, attenuated dengue virus;
- at least one of trehalose and sucrose;
- urea;
- a protein agent comprising human serum albumin (HSA);
- arginine;
- and
- at least one salt comprising sodium chloride (NaCl), sodium phosphate (Na2HPO4), potassium chloride (KCl) or potassium phosphate (KH2PO4);
- wherein the composition stabilizes the live, attenuated dengue virus.
A method for stabilizing live, attenuated dengue virus, the method comprising:
- combining live, attenuated dengue virus with a composition comprising:
- at least one of trehalose and sucrose;
- urea;
- human serum albumin (HSA);
- arginine;
- and
- at least one salt comprising sodium chloride (NaCl), sodium phosphate (Na2HPO4), potassium chloride (KCl) or potassium phosphate (KH2PO4);
- and
- lyophilizing the dengue virus composition,
- wherein the composition stabilizes the live, attenuated dengue virus.
Dependencies are inferred from the claim text.